THAR Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Tharimmune, Inc.'s net margin of -255.85%. Tharimmune, Inc.'s return on equity of -514.29% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Tharimmune, Inc. has a consensus price target of $5.00, signalling upside risk potential of 109.21%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -29.75%. Given that Tharimmune, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Tharimmune, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Tharimmune, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Tharimmune, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Tharimmune, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Tharimmune, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Tharimmune, Inc.'s net income of -$2.1M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Tharimmune, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 2.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tharimmune, Inc. is -- versus 2.35x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Phio Pharmaceuticals Corp. has a net margin of -- compared to Tharimmune, Inc.'s net margin of --. Tharimmune, Inc.'s return on equity of -514.29% beat Phio Pharmaceuticals Corp.'s return on equity of -95.19%.

Tharimmune, Inc. has a consensus price target of $5.00, signalling upside risk potential of 109.21%. On the other hand Phio Pharmaceuticals Corp. has an analysts' consensus of $14.00 which suggests that it could grow by 968.7%. Given that Phio Pharmaceuticals Corp. has higher upside potential than Tharimmune, Inc., analysts believe Phio Pharmaceuticals Corp. is more attractive than Tharimmune, Inc..

Tharimmune, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Phio Pharmaceuticals Corp. has a beta of 0.920, suggesting its less volatile than the S&P 500 by 7.968%.

Tharimmune, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phio Pharmaceuticals Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tharimmune, Inc. pays -- of its earnings as a dividend. Phio Pharmaceuticals Corp. pays out -- of its earnings as a dividend.

Tharimmune, Inc. quarterly revenues are --, which are smaller than Phio Pharmaceuticals Corp. quarterly revenues of --. Tharimmune, Inc.'s net income of -$2.1M is higher than Phio Pharmaceuticals Corp.'s net income of -$2.4M. Notably, Tharimmune, Inc.'s price-to-earnings ratio is -- while Phio Pharmaceuticals Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tharimmune, Inc. is -- versus -- for Phio Pharmaceuticals Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Tharimmune, Inc.'s net margin of --. Tharimmune, Inc.'s return on equity of -514.29% beat Palatin Technologies's return on equity of --.

Tharimmune, Inc. has a consensus price target of $5.00, signalling upside risk potential of 109.21%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Tharimmune, Inc., analysts believe Palatin Technologies is more attractive than Tharimmune, Inc..

Tharimmune, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Tharimmune, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tharimmune, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Tharimmune, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Tharimmune, Inc.'s net income of -$2.1M is higher than Palatin Technologies's net income of --. Notably, Tharimmune, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tharimmune, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.